Orbital Therapeutics
Expanding RNA medicines to more tissues, more diseases, and more patients.
26 employees · est. 2022 · Cambridge, United States
miRecule, Inc. is the older company (2016 vs 2022).
Side-by-Side Comparison
| Metric | miRecule, Inc. | Orbital Therapeutics |
|---|---|---|
| Founded | ||
| Founded | 2016 older | 2022 |
| Headquarters | ||
| Headquarters | Gaithersburg, United States | Cambridge, United States |
| Employees | ||
| Employees | 12 | 26 |
| Industry | ||
| Industry | Biopharma, Biotechnology, Health Care | Not tracked yet |
| Funding Stage | ||
| Funding Stage | Seed | Acquired |
| Total Funding | ||
| Total Funding | $7.20M | $1.77B |
| Funding Rounds | ||
| Funding Rounds | 3 | 3 |
| Services | ||
| Services | Development of RNA therapies for cancer and muscular dystrophy, Creation of antibody RNA conjugate therapeutics, Utilization of genomic and outcome data for therapeutic development, Expansion of strategic collaborations (e.g., with Sanofi) | RNA Medicine Development, Immunotherapy Design, Integrated RNA Platform, Clinical Trials, Research and Development |
| Target Customers | ||
| Target Customers | Patients with cancer, Patients with muscular dystrophy, Patients suffering from neuromuscular diseases, Healthcare providers specializing in rare genetic diseases | Patients with Autoimmune Diseases, Healthcare Providers, Pharmaceutical Companies, Research Institutions |
| Taxonomy | ||
| Taxonomy | RNA Therapeutics, First-in-Class Therapies, Head & Neck Squamous Cell Carcinoma, Facioscapulohumeral Muscular Dystrophy, Genomic Patient Data, Tailored Therapeutics, DREAmiR™ Platform, Genetic Alteration Targeting, RNA Therapeutics Development, Antibody RNA Conjugate (ARC), Genomic Medicine, Cancer Therapies, Muscular Dystrophy Therapies, Precision Medicine | RNA Medicines, Cell Reprogramming, Autoimmune Diseases, B Cell Depletion, Programmable Therapies, Targeted Delivery, AI-Guided Design, Circular RNA, Linear RNA, Oncology, Next-Generation Vaccines, Protein Therapeutics, RNA Science, Clinical Development |
| Website | ||
| Website | mirecule.com | orbitaltx.com |
About miRecule, Inc.
miRecule, Inc., a promising player in the RNA Therapeutics domain, is pioneering first-in-class RNA-based therapies, focusing on conditions such as Head & Neck Squamous Cell Carcinoma (HNSCC) and Facioscalpulohumeral Muscular Dystrophy (FSHD). Established in 2016, this United States-based startup op...
About Orbital Therapeutics
Orbital Therapeutics, founded in 2022 and headquartered in the United States, stands at the forefront of innovation in the burgeoning field of RNA medicines. The company's mission is succinctly encapsulated in its slogan: "Expanding RNA medicines to more tissues, more diseases, and more patients."...
We will tell you when either one moves
BounceWatch watches miRecule, Inc. and Orbital Therapeutics for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at miRecule, Inc. and Orbital Therapeutics — by email.
Frequently Asked Questions
Compare miRecule, Inc. with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at miRecule, Inc. on 11 Mar 2026, and Orbital Therapeutics on 11 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.